Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...

FloStent enabled catheter-free voiding in men with BPH-related urinary retention, showing potential as an interim solution before TURP. At three months, 72.7% of patients remained catheter-free, with ...

Dornier MedTech America launched the Hoover FANS and Axis II Slim ureteroscope for kidney stone treatment in the US, both FDA-cleared. The devices are designed to integrate with Dornier’s Thulio laser ...

FGFR inhibitors are vital in bladder cancer treatment but face challenges due to significant toxicities, limiting long-term use. Dabogratinib selectively targets FGFR3, aiming to reduce toxicities ...

Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies. Apolo emphasized the value of having robust monotherapy data before advancing into ...

Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab or ...

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

“The takeaway is that on a population level, on a health care system perspective, it's more cost-effective and safer to do transperineal prostate biopsy,” says Mitchell M. Huang, MD.

Cxbladder Triage test reduces cystoscopy and imaging in low-risk microscopic hematuria patients, optimizing diagnostic workflows. The study involved 3,353 patients, showing decreased cystoscopy and CT ...

The TRAVERSE trial showed testosterone therapy's MACE risk is non-inferior to placebo, reassuring prescribers and patients. Despite the updated labeling, caution is advised due to potential venous ...

The proposed budget cut reduces CDMRP funding from $1.509 billion in FY2024 to $650 million in FY2025, affecting cancer research funding. Organizations like Zero Prostate Cancer and the American ...